A new disposal breath-actuated inhaler was recently unveiled by Bang & Olufsen Medicom designed for use with liquid drug formulations suitable for pMDIs (pressurised metered dose inhalers). Manufacturers claim the inhaler, named Aspira, offers a “cost-effective and improved pulmonary drug delivery for treating diseases, including diabetes.”
Another key feature for the device is an integrated dose-counter, which can record up to 200 individual doses. This feature is important for people who have difficulties tracking their medication and can help with patient compliance issues. The dose counter will only register fired doses and will therefore reliably inform the patient of doses taken and remaining in the canister.